Stock Update (NASDAQ:AMGN): Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer

[PR Newswire] – THOUSAND OAKS, Calif., Nov. 24, 2014 /PRNewswire/ — Amgen (AMGN) today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase 3 RILOMET-1 . . . → Read More: Stock Update (NASDAQ:AMGN): Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer Similar Articles: Company Update (NASDAQ:AMGN): Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels Stock Update (NASDAQ:AMGN): The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival